Literature DB >> 2323525

Hyperviscosity syndrome in a hypercholesterolemic patient with primary biliary cirrhosis.

R S Rosenson1, A L Baker, M J Chow, R V Hay.   

Abstract

A 45-yr-old woman with primary biliary cirrhosis, xanthomatosis, and marked hypercholesterolemia developed symptoms of the hyperviscosity syndrome on three separate occasions. On presentation, she had a plasma total cholesterol concentration of 53.40 mM (2065 mg/dl) and a relative serum viscosity of 2.9. Following three courses of plasma exchange in a 5-day period, the total cholesterol level decreased to 6.75 mM (261 mg/dl) and the viscosity to 1.3. The cutaneous xanthomata were markedly diminished 1 wk following plasma exchange. Despite therapy with colestipol (30 g/d), the hyperviscosity syndrome developed 147 days later. This cycle recurred again 137 days after colestipol was discontinued. Serum viscosity and total cholesterol concentration were highly correlated during the postexchange or accumulation phases (R = 0.95, 95% CI: 0.85, 0.98) and during the exchange or interventional phases (R = 0.95, 95% CI: 0.84, 0.99). Serum viscosity was less significantly correlated with total serum protein (R = 0.84; 95% CI: 0.55, 0.95) or with plasma triglyceride (R = 0.63; 95% CI: 0.26, 0.81). There were no significant correlations of red cell mass, plasma fibrinogen levels, or serum bile salts with viscosity. Subfractionation of plasma into lipoprotein classes showed 45% of total cholesterol in the lipoprotein X fraction and a presumptive slow alpha-lipoprotein species. It is postulated that both the hyperviscosity syndrome and rapid resolution of xanthomata in the patient may be attributable to the physiology of her abnormal lipoprotein particles.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2323525     DOI: 10.1016/0016-5085(90)90356-6

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  6 in total

1.  Severe hypercholesterolemia associated with decreased hepatic triglyceride lipase activity and pseudohyponatremia in patients after allogeneic stem cell transplantation.

Authors:  Yoshihiro Inamoto; Tamio Teramoto; Koji Shirai; Hideko Tsukamoto; Takaomi Sanda; Koichi Miyamura; Ikuo Yamamori; Noriyuki Hirabayashi; Yoshihisa Kodera
Journal:  Int J Hematol       Date:  2005-11       Impact factor: 2.490

2.  Management of lipoprotein X and its complications in a patient with primary sclerosing cholangitis.

Authors:  Eric J Brandt; Shane M Regnier; Edward Ky Leung; Sharon H Chou; Beverly W Baron; Helen S Te; Michael H Davidson; Robert M Sargis
Journal:  Clin Lipidol       Date:  2015-08-01

3.  Detection of Lipoprotein X (LpX): A challenge in patients with severe hypercholesterolaemia.

Authors:  Agnieszka Ćwiklińska; Agnieszka Mickiewicz; Robert Kowalski; Barbara Kortas-Stempak; Agnieszka Kuchta; Krzysztof Mucha; Michał Makowiecki; Anna Gliwińska; Krzysztof Lewandowski; Leszek Pączek; Marcin Fijałkowski; Marcin Gruchała; Maciej Jankowski
Journal:  J Med Biochem       Date:  2020-09-02       Impact factor: 3.402

4.  A Simple Fluorescent Cholesterol Labeling Method to Cryoprotect and Detect Plasma Lipoprotein-X.

Authors:  Edward B Neufeld; Lita A Freeman; Vinay Durbhakula; Maureen L Sampson; Robert D Shamburek; Sotirios K Karathanasis; Alan T Remaley
Journal:  Biology (Basel)       Date:  2022-08-22

5.  LCAT protects against Lipoprotein-X formation in a murine model of drug-induced intrahepatic cholestasis.

Authors:  Marcelo J A Amar; Lita A Freeman; Takafumi Nishida; Maureen L Sampson; Milton Pryor; Boris L Vaisman; Edward B Neufeld; Sotirios K Karathanasis; Alan T Remaley
Journal:  Pharmacol Res Perspect       Date:  2019-12-29

6.  Monocyte phenotyping and management of lipoprotein X syndrome.

Authors:  Zeqin Lian; Anum Saeed; Xueying Peng; Xiaoyuan Dai Perrard; Xiaoming Jia; Aliza Hussain; Christie M Ballantyne; Huaizhu Wu
Journal:  J Clin Lipidol       Date:  2020-09-04       Impact factor: 4.766

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.